General Provisions - The company, Transwarp Technology (Shanghai) Co., Ltd., is established to meet the needs of modern enterprise systems and to protect the rights and interests of the company, shareholders, employees, and creditors [2][3] - The company is registered in Shanghai and has obtained a business license with a unified social credit code [2] - The company was registered by the China Securities Regulatory Commission (CSRC) for the initial public offering of A shares and H shares [3][4] Business Objectives and Scope - The company's business objective is to become a global leader in big data and artificial intelligence foundational software [5] - The registered business scope includes import and export of goods, technology services, software development, and computer system services [6] Shares - The company's shares are issued in the form of registered stocks, with each share having a nominal value of RMB 1 [8][19] - The total number of shares after the initial public offering of H shares is projected to be 8,470.5989 million shares, all of which are ordinary shares [10] Shareholders and Shareholder Meetings - Shareholders have the right to request the company to provide relevant materials and to participate in shareholder meetings [16][17] - The company must hold an annual general meeting within six months after the end of the previous fiscal year [49] - The company’s shareholder meetings can be held in a combination of physical and online formats [31] Rights and Obligations of Shareholders - Shareholders are entitled to dividends and other forms of profit distribution based on their shareholding [38] - Shareholders must comply with laws and regulations and are prohibited from abusing their rights to harm the interests of the company or other shareholders [41][42] Control and Management - The controlling shareholders and actual controllers must exercise their rights in accordance with laws and regulations, ensuring the interests of the listed company are maintained [43] - The board of directors is responsible for managing the company and must act in the best interests of the company and its shareholders [46]

证券代码：300904 证券简称：威力传动 公告编号：2025-047 银川威力传动技术股份有限公司 关于2024年员工持股计划第一个锁定期 （二）本期持股计划实施情况 公司于 2024 年 7 月 31 日收到中国证券登记结算有限责任公司深圳分公司 出具的《证券过户登记确认书》，"银川威力传动技术股份有限公司回购专用证 券账户"所持有的 335,366 股公司股票已于 2024 年 7 月 30 日以非交易过户的 方式过户至"银川威力传动技术股份有限公司—2024 年员工持股计划"，过户股 份数量占当时公司股本总额的 0.46%。具体内容详见公司于 2024 年 7 月 31 日在 巨潮资讯网（www.cninfo.com.cn）披露的相关公告。 （三）本期持股计划存续期及锁定期 根据本期持股计划的相关规定，本期持股计划的存续期为 48 个月，自公司 公告最后一笔标的股票过户至本次员工持股计划名下之日起算，即自 2024 年 7 月 30 日起至 2028 年 7 月 29 日止。 本期持股计划所获标的股票分三期解锁，解锁时点分别为自公司公告最后一 笔标的股票过户至本次员工持股计划名下之日起至满 12 个月 ...

证券代码：688143 证券简称：长盈通 公告编号：2025-048 武汉长盈通光电技术股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2024/7/18，由控股股东、实际控制人、董事长兼 总经理皮亚斌先生提议 回购方案实施期限 2024 年 7 月 17 日~2025 年 7 月 16 日 预计回购金额 2,000万元~4,000万元 回购价格上限 33.13元/股 □减少注册资本 √用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 实际回购股数 112.8759万股 实际回购股数占总股本比例 0.9224% 实际回购金额 2,284.66万元 实际回购价格区间 16.10元/股~27.11元/股 一、 回购审批情况和回购方案内容 （一）回购审批情况 盈通光电技术股份有限公司以集中竞价交易方式回购公司股份的函》，提议使用超 募资金以集中竞价交易方式回购公司股份，回购的股份将在未来适宜时机用于实 施员工持股计划或股权激励。 具 体 详 见 ...

Group 1: Company Overview and R&D - The company’s R&D expenses for 2024 are expected to increase by 10% year-on-year, focusing on the development of raw materials and formulations, as well as process optimization and technological innovation for mature products like vitamins [1] - The company has officially started selling para-hydroxyphenol in the PEEK field and is actively promoting its products, having completed sample submissions to major domestic PEEK manufacturers, currently in various validation stages [1] Group 2: Product Registration and Market Activities - The company holds registration certificates for two products: Fumaric Acid Bisoprolol Tablets and Lacosamide Injection, with the former having commenced market promotion and industrialization in 2024 [1] - There are currently no plans for stock incentive programs or share buybacks, although the company previously repurchased shares in 2019 and conducted a restricted stock incentive plan in 2015, along with the first employee stock ownership plan launched in 2021 [2] Group 3: Inventory and Capital Expenditure - The company’s large ending inventory balance is attributed to its diverse business segments, including vitamins, flavors, raw materials, leather chemicals, and chromium salts, consisting mainly of raw materials, work-in-progress, and finished products to meet varying customer demands [2] - Future capital expenditures will primarily focus on new project construction, such as a 600-ton iodinated contrast agent raw material project, and technological upgrades to existing projects aimed at cost reduction, efficiency enhancement, and improved safety and environmental control [2] Group 4: Risk Management - The company has not engaged in hedging activities and currently sees no demand for such services [2]

Meeting Overview - The first meeting of the 2025 Employee Stock Ownership Plan (ESOP) was held on July 16, 2025, with 23 participants representing 8,050,000 shares, which constitutes 100% of the total shares in the plan [1][2]. Resolutions Passed - The meeting approved the establishment of a management committee for the 2025 ESOP to enhance daily management efficiency, consisting of three members, including a chairperson [2][3]. - The committee members elected are Hua Xiangyang, Yao Hongxia, and Zheng Xinnian, with their term aligned with the duration of the 2025 ESOP [2][3]. - The management committee was authorized to handle all matters related to the 2025 ESOP, including asset liquidation and handling of disqualified holders' shares, with a unanimous approval of 8,050,000 shares [3].

Meeting Overview - The first meeting of the 2023 Employee Stock Ownership Plan (ESOP) was held on July 16, 2025, with 18 participants representing 8,817,978.20 shares, accounting for 100% of the voting rights [1][2] - The meeting was convened and presided over by the company's board secretary, Huang Rongfang, and complied with relevant laws and regulations [1] Resolutions Passed - The establishment of the 2023 ESOP Management Committee was approved to ensure the smooth implementation of the plan and protect the rights of the holders [1] - The committee will consist of three members, including one chairperson, with a term lasting for the duration of the ESOP [1] Voting Results - The resolution to establish the management committee received unanimous approval, with 8,817,978.20 votes in favor, representing 100% of the valid voting rights [2][3] - No votes were cast against or abstained from this resolution [2][3] Committee Elections - The election of Yang Xinping, Yan Xinhua, and Li Bin as members of the 2023 ESOP Management Committee was approved, with their term aligned with the ESOP duration [2] - The committee held its first meeting on the same day, electing Yang Xinping as the chairperson [2] Authorization - The meeting authorized the 2023 ESOP Management Committee to handle matters related to the ESOP, including changes in holders and share adjustments, effective until the termination of the ESOP [2]

Core Viewpoint - The company has successfully completed the first lock-up period of its 2024 employee stock ownership plan, allowing 45 eligible participants to unlock 30% of the initially granted shares, totaling 1.467 million shares, which represents 0.17% of the company's total share capital [2][7]. Implementation of Employee Stock Ownership Plan - The company held board meetings on June 14, 2024, and July 1, 2024, to approve the implementation of the employee stock ownership plan [2]. - On July 16, 2024, the company transferred 5.551 million shares to the dedicated account for the employee stock ownership plan, which accounted for 0.65% of the total share capital at that time [3]. - The stock ownership plan has three unlocking phases, with the first phase's unlocking conditions met on July 16, 2025 [3][4]. Performance Assessment - The performance assessment for the first lock-up period included company-level targets for revenue and innovation drug development progress [4]. - The company achieved its innovation drug development goals, with significant progress in clinical trials for multiple drugs, resulting in a 100% unlocking ratio for this performance metric [5][6]. - Individual performance assessments for the 45 participants were all rated B+ or above, meeting the criteria for full unlocking [7]. Future Arrangements - Following the unlocking of the first lock-up period, the employee stock ownership management committee will manage the rights of the participants according to the authorized decisions made in the meetings [8]. - The company will adhere to market trading rules and relevant regulations regarding stock transactions [8].

证券代码：600667 证券简称：太极实业 公告编号：临 2025-045 无锡市太极实业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡市太极实业股份有限公司（以下简称"公司"）太极实业·十一科技员 工持股计划（以下简称"员工持股计划"）2025 年第一次持有人会议于 2025 年 工持股计划管理委员会主任主持，应出席持有人 3 名，实际出席持有人 3 名，所 持有表决权员工持股计划份额 815,553 份，占公司员工持股计划总份额的 100%。 会议的召集、召开和表决程序符合相关法规和公司员工持股计划的规定。会议审 议并通过了如下议案： 议案内容：基于员工持股计划实施的实际情况以及持有人对公司持续稳定发 展的信心及公司股票价值的判断，拟将本次员工持股计划存续期再延长 12 个月， 即延长至 2026 年 7 月 17 日。 详情参见公司于 2025 年 7 月 17 日在上海证券交易所网站发布的《关于延长 员工持股计划存续期的公告》（公告编号：临 2025-046）。 表决结果：815,553 份同意（占 ...

证券代码：600667 证券简称：太极实业 公告编号：临 2025-046 市太极实业股份有限公司发行股份购买资产并募集配套资金暨关联交易报告书 （草案）>及其摘要的议案》以及相关议案，同意公司以非公开发行股票的方式 实施太极实业•十一科技员工持股计划，认购非公开发行股份不超过 200,000,000 股。（公告编号：临 2015-070、临 2015-078） 无锡市太极实业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡市太极实业股份有限公司（以下简称"公司"）太极实业•十一科技员工 持股计划（以下简称"员工持股计划"）的存续期将于 2025 年 7 月 17 日届满， 经公司太极实业•十一科技员工持股计划 2025 年第一次持有人会议和第十届董事 会第二十九次会议审议，同意将公司太极实业•十一科技员工持股计划存续期再 延长 12 个月，即延长至 2026 年 7 月 17 日，现将有关情况公告如下： 一、员工持股计划基本情况 公司于 2015 年 10 月 29 日、2015 年 11 月 16 日召开 ...

Group 1 - The first meeting of the 2025 Employee Stock Ownership Plan (ESOP) was held on July 16, 2025, with 83 participants representing 100% of the total shares in the plan [1][2] - The meeting approved the establishment of a management committee for the 2025 ESOP to oversee daily management and protect the rights of shareholders [2][3] - The management committee consists of three members, with a term aligned with the duration of the 2025 ESOP [2][3] Group 2 - The meeting elected Liu Zixin, Li Xiaoqing, and Liu Yanhui as committee members, ensuring no conflicts of interest with company executives [2][3] - The first committee meeting subsequently elected Liu Zixin as the committee chair [3] - The committee was authorized to manage various aspects of the ESOP, including qualification decisions, asset management, and representation of shareholders [4]